Jeffrey M. Jacobson,
MD

Jeffrey_Jacobson

Title:

Professor

Practice:

Drexel Infectious Disease and HIV

Specialty:

HIV, Infectious Diseases, Internal Medicine

Practicing Since:

1981

Locations:

Partnership Comprehensive Care Practice

1427 Vine Street
2nd Floor
Philadelphia, PA 19102
Phone: 215-762-2530
Fax: 215-762-2531
Conditions/Services
HIV; Immunocompromised patients
Biography

Dr. Jacobson is board certified in internal medicine and infectious disease. He sees patients at the Partnership Comprehensive Care Practice.

Positions:

  • Chair, Microbiome Focus Group of the AIDS Clinical Trials Group (ACTG)
  • Former chair, Translational Research and Drug Development Committee of the ACTG
  • Former chair, Immunology Research Agenda Committee of the ACTG
  • Editor, Immunotherapy for Infectious Diseases

In the News

Education
Cornell University (1973)
MD - Cornell University (1977)
Residency
Internal Medicine - Mount Sinai Hospital (1980)
Fellowship
Infectious Diseases - Mount Sinai Hospital (1982)
News/Publications

Selected Publications

"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody"
Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D’Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC
J Infect Dis; 201:1481-1487, 2010

"A randomized therapeutic vaccine trial of canarypox-HIV- pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy"
Gandhi RT, O’Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM
Vaccine; 27:6088-6094, 2009

"Safety, pharmacokinetics and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in HIV-1 infected adults"
Jacobson JM, Kuritzkes, DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST
Antimicrob Agents Chemother; 53:450-457, 2009

"Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults"
Jacobson JM, Saag MS, Thompson MA, et al.
Journal of Infectious Diseases, 198: 1345-52, 2008

"Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068"
Jacobson JM, Bucy RP, Spritzler J, et al.
Journal of Infectious Diseases, 194: 623-32, 2006

"Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542"
Jacobson JM, Israel RJ, Lowy I, Ostrow NA, et al.
Antimicrobial Agents and Chemotherapy, 48: 423-429, 2004

"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with human immunodeficiency virus type 1"
Kuritzkes DR, Jacobson JM, Powderly WG, et al.
Journal of Infectious Diseases, 189: 286-291, 2004

"Granulocyte-macrophage colony stimulating factor induces modest increases in plasma HIV-RNA and CD4 lymphocyte counts in patients with uncontrolled HIV infection"
Jacobson JM, Lederman MM, Spritzler J, et al. and the NIAID AIDS Clinical Trials Group
Journal of Infectious Diseases, 188: 1804-1814, 2003
   
"Thalidomide in low intermittent doses does not prevent HIV-associated aphthous ulcer recurrence"
Jacobson JM, Greenspan JS, Spritzler J, et al., and the NIAID AIDS Clinical Trials Group
Journal of Infectious Diseases, 183: 343-346, 2001
   
"A dose-escalation, phase I/II study of oral azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in patients with AIDS"
Jacobson JM, Hafner R, Holden-Wiltze J, Luft BJ, and the NIAID AIDS Clinical Trials Group
AIDS, 15: 583-589, 2001
   
"Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults"
Jacobson JM, Lowy I, Fletcher CV, et al. 
Journal of Infectious Diseases, 182: 326-329, 2000
   
"Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection"
Jacobson JM, Spritzler J, Fox L, et al., and the NIAID AIDS Clinical Trials Group
Journal of Infectious Diseases, 180: 61-67, 1999
   
"Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection"
Jacobson JM, Greenspan JS, Spritzler J, et al. 
New England Journal of Medicine, 336: 1487-93, 1997

"Pyrimethamine pharmacokinetics in HIV- infected patients seropositive for Toxoplasma gondii"
Jacobson JM, Davidian M, Rainey R, et al.
Antimicrobial Agents and Chemotherapy, 40: 1360-1365, 1996

"Passive immunotherapy in the treatment of advanced HIV infection"
Jacobson JM, Colman N, Ostrow N, Simson RW, Tomesch D, Marlin L, Rao ME, Mill J, Clemens J, and AM Prince
Journal of Infectious Diseases, 168: 298-305, 1993